Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.50 |
| ▸ | MGLL | Q99685 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12040646 | 1.00 | POLB (0.55) | POLBCA2MEN1KMT2ASIGMAR1 | |
| SCHEMBL5609865 | 0.98 | POLB (0.56) | POLBCA2MEN1KMT2AMGLL | |
| SCHEMBL12821019 | 0.92 | POLB (0.58) | POLBCA2MEN1KMT2AMAOB | |
| SCHEMBL27985650 | 0.83 | CA2 (0.67) | POLBCA2MEN1KMT2ASIGMAR1 | |
| SCHEMBL29314621 | 0.83 | SIGMAR1 (0.53) | POLBSIGMAR1MAPTRXFP1 | |
| SCHEMBL293285 | 0.83 | MAOB (0.54) | POLBCA2MEN1KMT2AMGLL | |
| SCHEMBL515212 | 0.83 | CA2 (0.53) | POLBCA2MEN1KMT2AMAOB | |
| SCHEMBL12040650 | 0.82 | CA2 (0.61) | POLBCA2MEN1KMT2ASIGMAR1 | |
| SCHEMBL10899010 | 0.81 | CA2 (0.63) | POLBCA2MEN1KMT2AMGLL | |
| SCHEMBL26073038 | 0.80 | POLB (0.47) | POLBCA2MEN1KMT2AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170196854-A1 | USE OF ANTHELMINTIC AGENTS AGAINST DIROFILARIA IMMITIS | INTERVET INC. (US) | 2017-07-13 | — | — | US | disclosed |
| US-9096524-B2 | Anthelmintic agents and their use | INTERVET INTERNATIONAL B.V. (NL) | 2015-08-04 | — | — | US | disclosed |
| US-20110319393-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319393-A1 | ANTHELMINTIC AGENTS AND THEIR USE | ACHE, ABCB11, MPO | POLB 3856/4885CA2 57/4885MEN1 1652/4885 |
| US-20170196854-A1 | USE OF ANTHELMINTIC AGENTS AGAINST DIROFILARIA IMMITIS | MPO, DHODH, DHX35 | POLB 4157/4885CA2 734/4885MEN1 3593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.